These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

888 related articles for article (PubMed ID: 25514100)

  • 21. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?
    Olszanecka-Glinianowicz M; Madej P; Zdun D; Bożentowicz-Wikarek M; Sikora J; Chudek J; Skałba P
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):55-61. PubMed ID: 22397743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
    Li L; Chen X; He Z; Zhao X; Huang L; Yang D
    J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
    Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.
    Cupisti S; Kajaia N; Dittrich R; Duezenli H; W Beckmann M; Mueller A
    Eur J Endocrinol; 2008 May; 158(5):711-9. PubMed ID: 18426831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.
    O'Reilly MW; Kempegowda P; Jenkinson C; Taylor AE; Quanson JL; Storbeck KH; Arlt W
    J Clin Endocrinol Metab; 2017 Mar; 102(3):840-848. PubMed ID: 27901631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
    Vassiliadi DA; Barber TM; Hughes BA; McCarthy MI; Wass JA; Franks S; Nightingale P; Tomlinson JW; Arlt W; Stewart PM
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3558-66. PubMed ID: 19567518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency.
    Carbunaru G; Prasad P; Scoccia B; Shea P; Hopwood N; Ziai F; Chang YT; Myers SE; Mason JI; Pang S
    J Clin Endocrinol Metab; 2004 Feb; 89(2):783-94. PubMed ID: 14764797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.
    Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM
    Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome.
    Rittmaster RS; Deshwal N; Lehman L
    J Clin Endocrinol Metab; 1993 May; 76(5):1295-300. PubMed ID: 8388405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome.
    Nadir A; Temizkan S; Ozderya A; Temizkan O; Orbay E; Aydin K
    Gynecol Endocrinol; 2019 Feb; 35(2):128-132. PubMed ID: 30324855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steroidogenic alterations and adrenal androgen excess in PCOS.
    Doi SA; Al-Zaid M; Towers PA; Scott CJ; Al-Shoumer KA
    Steroids; 2006 Sep; 71(9):751-9. PubMed ID: 16781743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
    Graff SK; Mário FM; Alves BC; Spritzer PM
    Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.
    Katsikis I; Karkanaki A; Misichronis G; Delkos D; Kandaraki EA; Panidis D
    Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):181-5. PubMed ID: 21353371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
    Ludwig AK; Goharian LG; Dietze T; Tauchert S; Rudolf S; Diedrich K; Schweiger U; Oltmanns KM
    Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.
    Zhou R; Bird IM; Dumesic DA; Abbott DH
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6630-7. PubMed ID: 16174719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body fat composition and distribution in women with polycystic ovary syndrome.
    Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
    Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.